ArticleMicrobiology spectrum2023
Emergence of KPC-113 and KPC-114 variants in ceftazidime-avibactam-resistant
Article in Microbiology spectrum, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 14 citations in OpenAlex.
- Investigating the prevalence of KPC-2 and the variant KPC-144 in carbapenem-resistant Klebsiella pneumoniae and elucidating its molecular epidemiological and genetic characteristics.BMC microbiology · 2026Article
- Within-host co-evolution of KPC variants: plasmid-mediated dissemination ofMicrobiology spectrum · 2026Article
- Genomic epidemiology of Carbapenem-Resistant Enterobacterales in southern Vietnam: dominance ofLe infezioni in medicina · 2026Article
- KPC-157 and KPC-181 carbapenemases produced by Citrobacter freundii ST522 and Klebsiella pneumoniae ST258 isolated from wastewater.Molecular biology reports · 2025Article
- Multispecies emergence of dualAntimicrobial agents and chemotherapy · 2025Article
- Reversion of KPC-114 to KPC-2 in ceftazidime-avibactam- resistant/meropenem-susceptibleMicrobiology spectrum · 2024Article
- First report of KPC variants conferring ceftazidime-avibactam resistance in Colombia: introducing KPC-197.Microbiology spectrum · 2024Article
- Genetic diversity of KPC-2-producing Klebsiella pneumoniae complex from aquatic ecosystems.World journal of microbiology & biotechnology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
Abstract
importanceKPC-2 carbapenemases are endemic in Latin America. In this regard, in 2018, ceftazidime-avibactam (CZA) was authorized for clinical use in Brazil due to its significant activity against KPC-2 producers. In recent years, reports of resistance to CZA have increased in this country, limiting its clinical application. In this study, we report the emergence of two novel KPC-2 variants, named KPC-113 and KPC-114, associated with CZA resistance in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.